The study enrolled 54 children aged under 18 years with suspected or confirmed malignancies between April 2023 and March 2025. Of these, 35 were prospectively recruited with fresh bone marrow, blood, or tissue samples collected at presentation or relapse, while 19 were analyzed retrospectively using archived frozen tissue. All cases underwent rapid whole genome sequencing using Illumina’s TruPath Genome technology, which enables on-flow-cell library preparation and eliminates separate DNA extraction and library synthesis steps that traditionally add weeks to the diagnostic timeline.

Researchers found that rapid sequencing reduced the mean end-to-end turnaround time from 42 days to just 3 days across the cohort. For hematological malignancies, where standard testing averaged 63 days, the rapid workflow achieved the same 3-day turnaround. For solid tumors, the reduction was from 29 days to 3 days. This acceleration matters enormously in pediatric oncology, where treatment decisions such as induction chemotherapy must often begin within days of presentation.

The detection performance was equally impressive. Across 104 samples representing 37 distinct pediatric cancer entities, rapid sequencing captured 147 of 155 clinically actionable somatic and germline variants identified by any method, a 95 percent detection rate. Standard NHS genomic testing detected 138 of 155 variants, or 89 percent. Seventeen clinically relevant variants were found exclusively by the rapid approach, and these additional findings directly benefited six patients in the cohort.

Among the 35 prospectively assessed patients, clinicians reported measurable improvements in care for 17 children, or 49 percent of the group. These improvements included faster access to targeted therapy, more accurate risk stratification, earlier clinical trial enrollment, and avoidance of unnecessary invasive procedures. Independent review of the 19 retrospective cases suggested that nearly half would have benefited if the rapid results had been available at the time of presentation.

Several individual cases illustrate the transformative potential of the approach. One child with pancreatic acinic cell carcinoma was found to harbor a novel NKD2-BRAF gene fusion, enabling targeted MEK pathway inhibition. Two children presenting with soft tissue lesions were diagnosed with non-malignant conditions, sparing them from unnecessary central venous catheter insertion and other invasive interventions. In one striking example, a patient was found to carry a pathognomonic ACVR1 germline variant confirming fibrodysplasia ossificans progressiva, a condition where even minor surgical trauma can trigger disabling soft-tissue calcification, making the diagnosis critical for avoiding harmful procedures.

For children with leukemia, the rapid workflow proved particularly powerful. Tumor-only sequencing from peripheral blood or bone marrow samples yielded minimal residual disease markers, cytogenetic risk stratification, and pharmacogenomic profiling within days from a single sample. In one infant with Down syndrome and suspected transient abnormal myelopoiesis, sequencing of a blood sample alone confirmed somatic GATA1 mutations and germline trisomy 21, supporting a surveillance approach and avoiding unnecessary chemotherapy despite a rising blast count. In several cases, blood sequencing alone provided sufficient diagnostic information, potentially sparing children from invasive bone marrow biopsies.

The technology behind the speed advantage lies in Illumina’s TruPath Genome platform, which uses flow-cell-bound transposomes to capture and tag long DNA molecules directly on the sequencing surface. This eliminates the need for separate library preparation and enables proximity information from neighboring nanowells to generate long-range genomic data. The result is haplotype phasing capability and improved structural variant detection, demonstrated in the study by the resolution of PMS2 variants to distinct parental alleles in a child with constitutional mismatch repair deficiency, confirming eligibility for immune checkpoint inhibitor therapy.

Mean sequencing depth reached 148-fold for somatic analysis and 83-fold for germline, exceeding the coverage achieved by standard NHS whole genome sequencing. The rapid workflow also performed equivalently on fresh and archival frozen specimens, including low-cellularity tumors that are notoriously challenging to diagnose. All variants identified exclusively by the rapid method were either confirmed through orthogonal testing or verified by manual inspection of corresponding standard sequencing data before being used to inform clinical management.

The authors acknowledge limitations including the relatively small cohort size, single-center design, and lack of randomization, noting that large-scale multi-center studies are needed to establish reproducibility, cost-effectiveness, and scalability within national healthcare frameworks. Nevertheless, the findings represent a compelling case for deploying rapid whole genome sequencing as a first-line diagnostic test in pediatric oncology, potentially reshaping how quickly children with cancer receive the genomic answers that guide their treatment.

Subject of Research: Rapid whole genome sequencing for pediatric cancer diagnosis

Article Title: Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis

Article References: Vedi, A., Trotman, J., Dias, J. M. L., Mijuskovic, M., Choi, S., Kingham, L., Moore, R. A., Leiter, S. M., Guermech, R., Semerene, A., Grisby, A., Wool, S., Joslin, V., Mahendrayogam, A., Abrams, J., Gattens, M., Blanco, E., Dickens, E. L., Burns, C., … Rowitch, D. (2026). Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis. Nature Communications, 17(1), Article 10078. https://doi.org/10.1038/s41467-026-77918-x

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77918-x

Keywords: whole genome sequencing, pediatric cancer, precision medicine, cancer genomics, rapid diagnostics, Illumina TruPath, NHS Genomic Medicine Service, hematological malignancies, solid tumors, targeted therapy, variant detection, turnaround time